Combination Kidney-Protective Therapy in Diabetic Kidney Disease: From RAAS Blockade to Multidrug Precision Nephrology
This review summarizes current and emerging evidence supporting combination kidney-protective therapy in DKD, including RAAS inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, finerenone, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), endothelin receptor antagonists, and aldosterone synthase inhibit...